Why the study?
Does intracoronary BQ-123 improve post-PCI coronary microvascular blood flow in patients with non-ST elevation acute coronary syndromes?
Population
23 patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention
Comparison
Intracoronary infusion of BQ-123 immediately… vs Intracoronary infusion of placebo immediately…
Design
RCT, randomised, double-blinded
Follow-up
16 hours post-PCI
Key result
Intracoronary infusion of the ETA receptor antagonist BQ-123 immediately before PCI significantly increased postprocedural average peak velocity compared with placebo (30 vs 19 cm/s; p=0.03).
Authors
Loading...
Intracoronary BQ-123 improves post-PCI microvascular flow in NSTACS; supports ETA antagonism as adjunctive therapy and warrants outcome trials.
RCT (n=23)
double-blinded
randomised
No
Does intracoronary BQ-123 improve post-PCI coronary microvascular blood flow in patients with non-ST elevation acute coronary syndromes?
Absolute Event Rate: 30% vs 19%
p-value: p=0.03
Adjunctive selective ETA antagonist BQ-123 administered before PCI in NSTACS patients significantly improves postprocedural coronary microvascular blood flow and reduces myocardial injury.
Guddeti et al. (2016) conducted an RCT in non-ST elevation acute coronary syndromes (NSTACS) (n=23). BQ-123 vs. placebo was evaluated on Post-PCI coronary microvascular blood flow (Doppler-derived average peak velocity) (p=0.03). Intracoronary infusion of the ETA receptor antagonist BQ-123 immediately before PCI significantly increased postprocedural average peak velocity compared with placebo (30 vs 19 cm/s; p=0.03).